ArticleBMC neurology2026
BRAF-amplified glioblastoma patients have a worse prognosis than those with BRAF mutation and are associated with amplification of MET, RHEB and CUL1.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is a treatment-challenging disease with a poor prognosis and few treatment options available. Patients with GBM with BRAF gene mutations are expected to benefit from targeted therapy with BRAF inhibitors.
methodsGenomic profiles, clinical and sample data, and tumor pathways were retrieved in a cohort of GBM patients with BRAF gene alterations. Statistical analysis was performed according to BRAF AMP, BRAF V600E, and BRAF non-V600E to study clinical features, survival curve analysis, tumor site, tumor signaling pathway and molecules.
resultsBRAF AMP and BRAF MUT include BRAF V600E and BRAF non-V600E in GBM patients account for the majority of BRAF-altered GBM. The prognosis of GBM patients with BRAF AMP is worse than that of patients with BRAF MUT, as well as BRAF V600E and BRAF non-V600E. The temporal lobe was primarily affected in GBM patients who carry BRAF gene alterations. CDKN2A DeepDel is a mutation associated with the BRAF variant GBM. In addition, BRAF AMP is often accompanied by amplified oncogenes, including MET, RHEB, and CUL1, as well as multiple types of mutations result in tumor suppressor genes in patients with BRAF non-V600E GBM including NF1 and TP53.
conclusionsDifferent BRAF gene alterations affect the prognosis of GBM and are associated with molecular alterations in classical tumor signaling pathways, and BRAF AMP is often accompanied by amplification of MET, RHEB, and CUL1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.